Journal
ANNALS OF DERMATOLOGY
Volume 22, Issue 3, Pages 349-352Publisher
KOREAN DERMATOLOGICAL ASSOC
DOI: 10.5021/ad.2010.22.3.349
Keywords
Atopic dermatitis; Biologies; Omalizumab
Categories
Ask authors/readers for more resources
Atopic dermatitis (AD) is a chronic cutaneous inflammatory disease. Various categories of therapeutic medications are used for treating AD. Omalizumab is a monoclonal anti-IgE antibody that binds to IgE molecules at the high-affinity receptor (Fc epsilon RI) binding site. Therefore, omalizumab can be used as a potential new systemic treatment agent for recalcitrant AD patients with elevated IgE levels. A 34-year-old man had been treated for AD with several topical and oral agents. However, he was refractory to these therapies and his serum IgE levels were very high. We treated him with omalizumab. After 8 months of the treatment, his symptoms were notably improved and the SCORAD index was decreased. Thus, we report on the first case of recalcitrant AD that was successfully treated with omalizumab in Korea. (Ann Dermatol 22(3) 349 similar to 352, 2010)
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available